BRCA2 and cancer: Furthermore, treatment with the PARP inhibitor olaparib upregulates PD-L1 expression through the formation of cytotoxic DSBs and activation of ATM/ATR/Chk1 kinases in BRCA2-depleted cancer cells independent of the IFN pathway [47].